B · Normal
[Enhua Pharmaceutical: Obtained Drug Registration Certificate for Oxycodone Hydrochloride Sustained-Release Tablets] On November 16th, Enhua Pharmaceutical (002262.SZ) announced that the company had recently obtained the Drug Registration Certificate for the chemical drug Oxycodone Hydrochloride Sustained-release Tablets approved and issued by the State Drug Administration, with a specification of 10 mg. The drug is an abuse-proof sustained-release formulation independently developed by the company, and is used to treat pain severe enough to require long-term, continuous, daily use of opioids on time. This approval is a new 10mg specification based on the original 40mg specification, which can better meet the individualized dose escalation needs of patients, enrich the company's product pipeline in the field of central analgesics, and help enhance market competitiveness.
Comments